Related Experiment Video

Updated: Jul 25, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship

Ke Xu1, Hao Tang1, Jie Xiong2

  • 1Department of Cardiology, The First Hospital of Harbin Medical University, Youzheng Street 23#, Nangang District, Harbin, 150001, Heilongjiang Province, China.

European Journal of Pharmacology
|June 27, 2023
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) used in cancer therapy can paradoxically promote or prevent atherosclerosis. This review examines how novel TKIs impact atherosclerosis, highlighting the need for further research into their cardiovascular effects.

Area of Science:

  • Oncology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Targeted cancer therapies, particularly tyrosine kinase inhibitors (TKIs), have transformed cancer treatment.
  • Clinical and experimental data reveal that TKIs possess dual roles in atherosclerosis, capable of both inducing and preventing it.
  • This duality necessitates a deeper understanding of their cardiovascular impact.

Purpose of the Study:

  • To review and synthesize existing clinical and basic experimental findings on the effects of TKIs on atherosclerosis.
  • To elucidate how the specific mechanisms of novel TKIs influence atherosclerosis development and progression.
  • To address the contradictory roles of TKIs in cardiovascular health.

Main Methods:

  • Comprehensive literature review of clinical trials and preclinical studies.
  • Analysis of data on atherosclerosis-inducing and -preventing properties of various TKIs.
  • Examination of the targeted mechanisms of novel TKIs in relation to atherosclerosis.

Main Results:

  • TKIs exhibit a complex relationship with atherosclerosis, with some promoting cardiovascular events and others showing protective effects.
  • Specific TKI drugs demonstrate distinct impacts on atherosclerosis regulation, influenced by their targeted pathways and patient conditions.
  • Novel TKIs present varied effects on atherosclerosis, underscoring the need for nuanced evaluation.

Conclusions:

  • The role of TKIs in atherosclerosis is multifaceted and drug-specific.
  • Further research is crucial to fully understand the association between TKIs and atherosclerosis.
  • Collaborative efforts are needed to guide clinical practice and mitigate cardiovascular risks associated with TKI therapy.
Keywords:
Adverse coronary artery diseaseAtherosclerosisCancerChemotherapyTyrosine kinase inhibitor (TKI)

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
13
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K